A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy

Rate and patient features associated with recurrence of acute myocarditis

BACKGROUND

Rate and patient features associated with recurrence after acute myocarditis are largely unknown.

METHODS AND RESULTS

First recurrence of acute myocarditis was studied in 1662 patients aged 16-70 years using a registry data of 29 hospitals in Finland (median follow-up 4.5 years). Matched intoxication patients served as controls. Incidence rate of first time hospitalization due to acute myocarditis was 5.52 (CI 5.26-5.79) per 100,000 person-years during 2001-2008. During the first 30 days 5.5% (CI 3.5-4.4%) of patients were re-admitted to hospital with acute myocarditis (p<0.0001 vs. controls). After 30 days, recurrence rate was 7.0% (CI 5.7-8.6%; p<0.0001 vs. controls). Acute myocarditis recurred after 365 days in 4.7% (CI 3.2-6.7%) of patients (p<0.0001 vs. controls). During the whole follow-up, recurrence rate was 10.3% (CI 8.8-12.1%; p<0.0001 vs. controls) with median recurrence time of 34.5 days. Prolonged (>7 days) initial admission was associated with recurrences during (HR 2.9; CI 1.6-5.2) and after first month (HR 1.8; CI 1.2-3.2), and overall (HR 2.0; CI 1.3-3.2). Ventricular arrhythmia at initial occurrence was associated with recurrence after 30 days (HR 8.6; CI 2.5-30.1), after 1 year (HR 22.6; CI 2.5-201.4) and overall (HR 6.7; CI 2.3-6.7). Other features associated with recurrence were younger age (>365 days), inflammatory bowel disease (during first month), and chronic pulmonary disease (≥ 30 days).

CONCLUSIONS

Acute myocarditis reoccurs in a significant proportion of patients. Prolonged initial admission, ventricular arrhythmias, younger age, inflammatory bowel disease and chronic pulmonary disease are associated with recurrences at different phases after acute myocarditis.

Systematic permutation testing in GWAS pathway analyses: identification of genetic networks in dilated cardiomyopathy and ulcerative colitis

Background

Genome wide association studies (GWAS) are applied to identify genetic loci, which are associated with complex traits and human diseases. Analogous to the evolution of gene expression analyses, pathway analyses have emerged as important tools to uncover functional networks of genome-wide association data. Usually, pathway analyses combine statistical methods with a priori available biological knowledge. To determine significance thresholds for associated pathways, correction for multiple testing and over-representation permutation testing is applied.

Results

We systematically investigated the impact of three different permutation test approaches for over-representation analysis to detect false positive pathway candidates and evaluate them on genome-wide association data of Dilated Cardiomyopathy (DCM) and Ulcerative Colitis (UC). Our results provide evidence that the gold standard - permuting the case–control status – effectively improves specificity of GWAS pathway analysis. Although permutation of SNPs does not maintain linkage disequilibrium (LD), these permutations represent an alternative for GWAS data when case–control permutations are not possible. Gene permutations, however, did not add significantly to the specificity. Finally, we provide estimates on the required number of permutations for the investigated approaches.

Conclusions

To discover potential false positive functional pathway candidates and to support the results from standard statistical tests such as the Hypergeometric test, permutation tests of case control data should be carried out. The most reasonable alternative was case–control permutation, if this is not possible, SNP permutations may be carried out. Our study also demonstrates that significance values converge rapidly with an increasing number of permutations. By applying the described statistical framework we were able to discover axon guidance, focal adhesion and calcium signaling as important DCM-related pathways and Intestinal immune network for IgA production as most significant UC pathway.

Almanac 2014: cardiomyopathies

Cardiomyopathies are myocardial disorders that are not explained by abnormal loading conditions and coronary artery disease. They are classified into a number of morphological and functional phenotypes that can be caused by genetic and non-genetic mechanisms. The dominant themes in papers published in 2012-2013 are similar to those reported in Almanac 2011, namely, the use (and interpretation) of genetic testing, development and application of novel non-invasive imaging techniques and use of serum biomarkers for diagnosis and prognosis. An important innovation since the last Almanac is the development of more sophisticated models for predicting adverse clinical events.

[Ventricular tachycardia : Treatment and prognostic significance]

Dilative cardiomyopathy (DCM) has an incidence of 5-8/100,000 inhabitants, and hypertrophic cardiomyopathy an incidence of 1/500 inhabitants. Depending on specific risk factors both conditions have an increased risk for sudden cardiac death (SCD): in DCM reduced left ventricular ejection fraction and reduced physical capacity; and in HCM SCD in family members, left ventricular septum  > 30 mm, unclear syncope, non-sustained ventricular tachycardia (VT) on holter-ECG and inadequate blood pressure response on ergometer. Especially patients with intermediary risk factors are insufficiently classified, and the lifesaving implantation of a cardioverter-defibrillator (ICD) often leads to a significant number of device-related complications. In this area additional methods like late enhancement imaging with cardio MRI, identification of genetic variation and ECG characteristics could help improve risk stratification in these patients.